Sanofi, Global Genomics Group Partner
Complete the form below to unlock access to ALL audio articles.
Under the terms of the agreement, Sanofi and G3 will utilize G3's proprietary platform with data from its G3LOBAL DatabaseTM to further unravel the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with such novel signaling pathways.
"Our G3LOBAL DatabaseTM has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process," said Szilard Voros, M.D., founder and chief executive officer of G3. "We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways."
G3 will receive undisclosed payments from Sanofi for the collaboration.
